Quadriplegia secondary to abiraterone-induced severe hypokalemia

CC BY-NC-ND 4.0 · South Asian J Cancer 2019; 08(03): 139-144
DOI: 10.4103/sajc.sajc_343_18

Letter to the Editor

Jignesh B. Rajvanshi

DNB Medical Oncology Resident, Department of Medical Oncology, Apollo CBCC Cancer Care, Ahmedabad, Gujarat

,

Manin D. Chaudhary

DNB Medical Oncology Resident, Department of Medical Oncology, Apollo CBCC Cancer Care, Ahmedabad, Gujarat

,

Priyanka D. Malekar

DNB Surgical Oncology Resident, Department of Medical Oncology, Apollo CBCC Cancer Care, Ahmedabad, Gujarat

,

Nitin K. Singhal

Consultant Surgical Oncology, Department of Medical Oncology, Apollo CBCC Cancer Care, Ahmedabad, Gujarat

,

Shirish S. Alurkar

Chief Director, Department of Medical Oncology, Apollo CBCC Cancer Care, Ahmedabad, Gujarat

References
1 de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005.
2 Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: Final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012;13:983-92.
3 Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 2017;377:352-60.
4 James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. STAMPEDE Investigators abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 2017;377:338.